Optimization and Individualization of Medication Selection and Dosing

1 - 39 . (canceled)

40 . A method for treating a patient with a therapeutic drug, the method comprising

receiving a drug profile comprising the drug's therapeutic range;

receiving patient data comprising demographic data and clinical data;

determining the patient's genotype at one or more genetic loci encoding a cytochrome P450 gene selected from the group consisting of CYP2D6, CYP1A2, CYP2C19, CYP2C9, and CYP2E1, each genetic loci containing one or more genetic variants;

generating a first pharmacokinetic (PK) model of the area under the time concentration curve (AUC) based on the patient data, genotype, and drug profile, wherein the model is a Bayesian model and incorporates the one or more genetic variations, a population frequency for each genetic variation, and AUC data for each genetic variation;

administering a first dosing regimen of the drug to the patient based upon the first PK model;

determining a blood level of the drug in the patient;

generating a second PK model incorporating the blood level of the drug;

administering a second dosing regimen of the drug to the patient based upon the second PK model.

41 . The method of claim 40 , wherein the step of determining the blood level of the drug comprises determining a pre-dose blood level of the drug in the patient before administering the first dosing regimen.

42 . The method of claim 41 , wherein the method further comprises incorporating the pre-dose blood level into the PK model.

43 . The method of claim 40 , wherein the therapeutic drug is a neuropsychiatric medication.

44 . The method of claim 43 , wherein the neuropsychiatric medication is a selective serotonin reuptake inhibitor or a tricyclic antidepressant.

45 . The method of claim 43 , wherein the neuropsychiatric medication is a substrate of CYP2D6.

46 . The method of claim 45 , wherein the medication is selected from the group consisting of amitriptyline, nortriptyline, haloperidol, and desipramine.

47 . The method of claim 43 , wherein the neuropsychiatric medication is a substrate of CYP1A2.

48 . The method of claim 47 , wherein the medication is selected from clozapine and imipramine.

49 . The method of claim 43 , wherein the neuropsychiatric medication is a substrate of CYP2C19.

50 . The method of claim 49 , wherein the medication is selected from imipramine, citalopram, and diazepam.

51 . The method of claim 43 , wherein the neuropsychiatric medication is a substrate of CYP2C9.

52 . The method of claim 51 , wherein the medication is selected from acetaminophen and antabuse (disulfiram).

53 . The method of claim 43 , wherein the neuropsychiatric medication is a substrate of CYP2E1.

54 . The method of claim 53 , wherein the medication is selected from phenytoin and carbamazepine.